Esperion scores FDA nod for cholesterol-buster Nexletol
admin 21st February 2020 Uncategorised 0Esperion has had a rocky road to approval for its LDL-cholesterol-lowering drug Nexletol after a late-stage trial in 2018 threatened to derail its quest. But after backing its drug up with strong safety data, Esperion has the green light to
read more